Malaria: Immunity

Abstract

Malaria, a vector‐borne disease caused by Plasmodium parasites, remains a major cause of morbidity and mortality in the developing world. To attain a substantial and steady decline in disease and deaths, a safe and efficacious vaccine is an indispensable tool. However, fundamental to the discovery, design and development of a malaria vaccine is a comprehensive knowledge of the induction and regulation of protective immune responses against the parasite. To this end, studies utilizing animal models, naïve human volunteers and individuals living in malaria endemic areas have provided important insights regarding the different mechanisms of antimalaria immunity.

Keywords: malaria; Plasmodium; immunity; protection; vaccine

Figure 1.

Plasmodium life cycle progression in the mammalian host and major targets of antiparasite immune responses. The malaria parasite is transmitted during the probing phase of a female Anopheles mosquito that delivers around a dozen sporozoites into the skin. Sporozoites are highly motile and rapidly enter a nearby capillary from where they eventually reach the liver. Sporozoites actively enter a suitable hepatocyte and commence intracellular transformation and replication. During EEF development, an infected hepatocyte will produce tens of thousands of pathogenic merozoites that egress out of the liver. Merozoites actively penetrate erythrocytes where they develop into growth stages (trophozoites) and finally into 16–32 new merozoites that initiate another blood stage cycle. A subpopulation of asexual blood stages will transform into male (pink) and female (blue) sexual stages that are transmitted to the Anopheles mosquito. Antibody‐mediated protection may occur neutralizing the extracellular invasion stages (sporozoites and merozoites). Cellular immunity largely acts against the intracellular EEFs.

close

References

Cohen S, McGregor IA and Carrington S (1961) Gamma‐globulin and acquired immunity to human malaria. Nature 192: 733–737.

Guinovart C, Navia MM, Tanner M and Alonso PL (2006) Malaria: burden of disease. Current Molecular Medicine 6: 137–140.

Hafalla JC, Cockburn IA and Zavala F (2006) Protective and pathogenic roles of CD8+ T cells during malaria infection. Parasite Immunology 28: 15–24.

Kumar KA, Sano G‐I, Boscardin S et al. (2006) The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites. Nature 444: 937–940.

Mueller A‐K, Labaied M, Kappe SHI and Matuschewski K (2005) Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 433: 164–167.

Nussenzweig RS, Vanderberg J, Most H and Orton C (1967) Protective immunity produced by the injection of x‐irradiated sporozoites of Plasmodium berghei. Nature 216: 160–162.

Plebanski M, Lee EA, Hannan CM et al. (1999) Altered peptide ligands narrow the repertoire of cellular immune responses by interfering with T‐cell priming. Nature Medicine 5: 565–571.

Pombo DJ, Lawrence G, Hirunpetcharat C et al. (2002) Immunity to malaria after administration of ultra‐doses of red cells infected with Plasmodium falciparum. Lancet 36: 610–617.

Reece WH, Pinder M, Gothard PK et al. (2004) A CD4+ T‐cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nature Medicine 10: 406–410.

Salanti A, Dahlback M, Turner L et al. (2004) Evidence for the involvement of VAR2CSA in pregnancy‐associated malaria. Journal of Experimental Medicine 200(9): 1197–1203.

Schofield L, Villaquiran J, Ferreira A et al. (1987) Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature 330: 664–666.

Yoshida N, Nussenzweig RS, Potocnjak P, Nussenzweig V and Aikawa M (1980) Hybridoma produces antibodies directed against the sporozoite stage of malaria parasite. Science 207: 71–73.

Further Reading

Boutlis CS, Riley EM, Anstey NM and de Souza JB (2005) Glycosylphosphatidylinositols in malaria pathogenesis and immunity: potential for therapeutic inhibition and vaccination. Current Topics in Microbiology and Immunology 297: 145–185.

Kaslow DC (2002) Transmission‐blocking vaccines. Chemical Immunology 80: 287–307.

Marsh K and Kinyanjui S (2006) Immune effector mechanisms in malaria. Parasite Immunology 28: 51–60.

Matuschewski K (2006) Vaccine development against malaria. Current Opinion in Immunology 18: 449–457.

Stevenson MM and Riley EM (2004) Innate immunity to malaria. Nature Review of Immunology 4: 169–180.

Wassmer SC, Combes V and Grau GE (2003) Pathophysiology of cerebral malaria: role of host cells in the modulation of cytoadhesion. Annals of the New York Academy of Science 992: 30–38.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Hafalla, Julius Clemence R, Matuschewski, Kai, and Mueller, Ann‐Kristin(Dec 2007) Malaria: Immunity. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0020183]